Brief: Intelgenx Announces FDA’S Acceptance Of Resubmitted Rizaport New Drug Application
22/10/2019 13:10
Oct 22 (Reuters) - Intelgenx Technologies Corp IGX.V :
* INTELGENX ANNOUNCES FDA’S ACCEPTANCE OF RESUBMITTED
RIZAPORT®
NEW DRUG APPLICATION
* INTELGENX TECHNOLOGIES CORP - FDA HAS ASSIGNED A PDUFA
GOAL
DATE FOR COMPLETION OF REVIEW OF RIZAPORT NDA OF MARCH 26, 2020
Source text for Eikon: ID:nGNXM0ncn
Further company coverage: IGX.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelgenx Technologies
See all newsBrief: Intelgenx Obtains Court-Approval Of Sale & Investment Solicitation Process
Brief: Intelgenx Initiates Restructuring Proceedings Under CCAA To Implement Review Of Its Strategic Alternatives
Brief: Intelgenx Initiates Restructuring Proceedings Under The CCAA
Brief: IntelGenx Says First Parkinson’s Disease Patients Dosed With Montelukast VersaFilm in Mid-Stage Clinical Trial
Brief: IntelGenx Updates Status Of Buprenorphine Buccal Film ANDA